| Title |
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2008
|
| DOI | 10.2147/tcrm.s1526 |
| Pubmed ID | |
| Authors |
Omar S Din, Penella J Woll |
| Abstract |
Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Mutations in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase receptor, an important factor in the pathogenesis of the disease. The development of specific tyrosine kinase inhibitors, such as imatinib mesylate, has led to a breakthrough in the treatment of advanced GIST. Treatment with this drug has led to significant improvements in survival, with overall response rates in excess of 80%. Side effects are common, but usually manageable. The success of this drug has led to further trials investigating its use in the pre- and postoperative situation. This review summarizes the current knowledge of GIST and imatinib treatment and possible future developments. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 78 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 16% |
| Student > Postgraduate | 13 | 16% |
| Student > Ph. D. Student | 10 | 13% |
| Student > Bachelor | 9 | 11% |
| Student > Doctoral Student | 6 | 8% |
| Other | 13 | 16% |
| Unknown | 16 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 36% |
| Agricultural and Biological Sciences | 11 | 14% |
| Biochemistry, Genetics and Molecular Biology | 10 | 13% |
| Chemistry | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2017.
All research outputs
#7,356,550
of 25,374,917 outputs
Outputs from Therapeutics and Clinical Risk Management
#379
of 1,323 outputs
Outputs of similar age
#39,535
of 172,957 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#14
of 21 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,957 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.